# EQUULEUS (daratumumab): what clinicians are saying

> 244 statements from 15 sources (4 videos, 5 posts, 6 papers), 93 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 18, 2026.

## Report

- Trial: An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma
- NCT ID: NCT01998971
- Registry: https://clinicaltrials.gov/study/NCT01998971
- Sponsor: Janssen Research & Development, LLC
- Phase: Phase 1
- Status: Completed
- Drugs tested: daratumumab plus carfilzomib plus dexamethasone; daratumumab plus pomalidomide plus dexamethasone; daratumumab plus carfilzomib plus lenalidomide plus dexamethasone
- Indication: multiple myeloma
- Version: v1.0.0, edition 1
- Accepted: 2026-11-18 UTC
- Last checked: 2026-11-18 UTC
- Release hash: 374c6994c036abcabe3cb997b08067da524e4e06d5d8b13016d2d1ea6299b1de

## Counts

- Commentary sources screened: 34
- Sources cited by verified statements: 15
- Verified statements: 244
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 93
- Findings: 15
- Named people in screened sources (unnamed speakers and accounts not counted): 9
- Speakers cited: 9
- Cited speakers with a verified identity: 7
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 7
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 7
- By role and specialty (the abstract's specialty counts):
  - 4 physician, specialty not confirmed
  - 3 physician, Medical oncology
- Organisational or shared accounts (not counted as people): 4

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A physician supports weekly D-Kd in EQUULEUS while relaying a cross-study comparison suggesting similar benefit and safety; this does not establish schedule equivalence. A medical oncologist considers prior treatment and refractoriness relevant to D-Pd/Isa-Pd selection but offers no sequencing rule. Direct commentary on the trial is brief; broader discussion of frontline anti-CD38 combinations and maintenance provides context rather than evidence of this trial’s outcomes.

## Findings (titles)

- F1. Weekly KdD70: why a clinician welcomes the dosing option
  - 9 statements from 1 speaker in 4 sources.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 7 cited clinicians.
- F3. Anti-CD38–pomalidomide triplets: a clinician weighs prior lines and refractory status
  - 3 statements from 1 speaker in 2 sources.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 7 cited clinicians.
- F4. D-Kd: a clinician welcomes approval but hopes for future regional access
  - 1 statement from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “hope for future regional access”.
  - 1 of the report's 7 cited clinicians.
- F2. DREAMM-7: how a speaker weighs potential benefit against vision risks
  - 7 statements from 1 speaker in 1 source, a podcast or video.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F5. Single-drug maintenance: a clinician favors daratumumab over lenalidomide
  - 3 statements from 1 speaker in 1 source, a podcast or video.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 7 cited clinicians.
- F6. CD38 maintenance: how a clinician weighs CD38-naïve data against post-quadruplet gaps
  - 16 statements from 1 speaker in 2 sources, all podcasts or videos.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 7 cited clinicians.
- F7. MRD-informed treatment reduction: where clinicians split on whether and when to stop
  - 26 statements from 4 speakers in 4 sources, all podcasts or videos.
  - 3 of the 4 named speakers in this finding take a side on this question: 2 on one side, 2 on the other, 1 on both; every named speaker in this finding is a confirmed clinician.
  - 4 of the report's 7 cited clinicians.
- F8. Transplant deferral: how clinicians weigh MRD, disease risk and fitness
  - 13 statements from 2 speakers in 2 sources, all podcasts or videos.
  - 2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other; every named speaker in this finding is a confirmed clinician.
  - 2 of the report's 7 cited clinicians.
- F9. Frontline quadruplets: most clinicians favor use, but one flags uneven uptake
  - 27 statements from 3 speakers in 4 sources, all podcasts or videos.
  - 2 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one flags uneven uptake”.
  - 3 of the report's 7 cited clinicians.
- F10. Quadruplets in older age: why most clinicians favor selected use with dose adjustments
  - 22 statements from 3 speakers in 3 sources, all podcasts or videos.
  - 2 of the 3 named speakers in this finding hold this view, each a confirmed clinician.
  - 3 of the report's 7 cited clinicians.
- F11. Early dexamethasone stopping: a clinician sees a future template, not a universal rule
  - 9 statements from 3 speakers in 2 sources, all podcasts or videos.
  - 1 of the 3 named speakers in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “not a universal rule”.
  - 2 of the report's 7 cited clinicians.
- F12. Carfilzomib: how a clinician weighs neuropathy, disease risk, access and cardiac risk
  - 18 statements from 2 speakers in 2 sources, all podcasts or videos.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician.
  - 2 of the report's 7 cited clinicians.
- F13. Lenalidomide: a clinician favors early use but awaits stable renal function
  - 6 statements from 1 speaker in 1 source, a podcast or video.
  - The one named speaker in this finding holds this view, a confirmed clinician; 1 of the 1 holds its caveat, “await stable renal function”.
  - 1 of the report's 7 cited clinicians.
- F14. CD38 antibodies: how clinicians weigh dosing and delivery experience
  - 14 statements from 2 speakers in 3 sources, all podcasts or videos.
  - 2 of the 2 named speakers in this finding hold this view, each a confirmed clinician.
  - 2 of the report's 7 cited clinicians.
- F15. CD38 care: a clinician stresses prevention; one plans for long-term therapy
  - 16 statements from 2 speakers in 2 sources, all podcasts or videos.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of the 2 holds its caveat, “one plans for long-term therapy”.
  - 2 of the report's 7 cited clinicians.

11 of the 15 findings and 162 of the 244 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 9 | 6 | 4 | 1 | 3 |
| F3 | 3 | 4 | 2 | 1 | 2 |
| F4 | 1 | 2 | 1 | 1 | 1 |
| F2 | 7 | 5 | 1 | 1 | 3 |
| F5 | 3 | 3 | 1 | 1 | 2 |
| F6 | 16 | 10 | 2 | 1 | 4 |
| F7 | 26 | 16 | 4 | 4 | 5 |
| F8 | 13 | 8 | 2 | 2 | 4 |
| F9 | 27 | 18 | 4 | 3 | 3 |
| F10 | 22 | 12 | 3 | 3 | 4 |
| F11 | 9 | 6 | 2 | 3 | 3 |
| F12 | 18 | 15 | 2 | 2 | 4 |
| F13 | 6 | 3 | 1 | 1 | 2 |
| F14 | 14 | 9 | 3 | 2 | 4 |
| F15 | 16 | 9 | 2 | 2 | 5 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 2 | 0 | 0 | 2 | 5 | 9 | 1 | 2 posts and articles, 2 publications |
| F3 | 2 | 0 | 0 | 0 | 1 | 3 | 1 | 2 posts and articles |
| F4 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 post or article |
| F2 | 2 | 2 | 1 | 1 | 1 | 8 | 2 | 1 podcast or video |
| F5 | 2 | 0 | 0 | 0 | 1 | 3 | 2 | 1 podcast or video |
| F6 | 5 | 6 | 0 | 1 | 4 | 18 | 3 | 2 podcasts and video |
| F7 | 8 | 8 | 4 | 1 | 5 | 29 | 1 | 4 podcasts and video |
| F8 | 5 | 3 | 3 | 1 | 1 | 14 | 2 | 2 podcasts and video |
| F9 | 19 | 1 | 1 | 3 | 3 | 28 | 1 | 4 podcasts and video |
| F10 | 11 | 3 | 2 | 0 | 6 | 23 | 2 | 3 podcasts and video |
| F11 | 7 | 0 | 1 | 0 | 1 | 10 | 2 | 2 podcasts and video |
| F12 | 10 | 2 | 3 | 1 | 2 | 19 | 3 | 2 podcasts and video |
| F13 | 2 | 0 | 4 | 0 | 0 | 6 | 0 | 1 podcast or video |
| F14 | 6 | 2 | 3 | 3 | 0 | 14 | 1 | 3 podcasts and video |
| F15 | 13 | 1 | 2 | 0 | 0 | 18 | 0 | 2 podcasts and video |

### Trial dimensions

- Primary endpoint: Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT): F1 (2 shared claims)
- Primary endpoint: Number of participants affected by dose-limiting toxicities: no finding draws on it directly
- Secondary endpoints: F1 (2 shared claims)
- Population and setting: F3 (2 shared claims), F4 (1 shared claims)
- The comparison: F1 (3 shared claims), F3 (1 shared claims)
- Safety and tolerability: F1 (2 shared claims)
- Design and conduct: F1 (2 shared claims)

## Abbreviations

- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- MRD: measurable residual disease
- NPI: National Provider Identifier, the US registry number for clinicians

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 15 | Titles free |
| Detailed analysis | 17 sections | Paid |
| Verified statements with short source quotes and links | 244 | Paid |
| Who said each statement: the cited speakers | 9 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 7 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 7 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 20 | Free |
| Sources with links | 15 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 7 of the 9 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

19 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT) | discussed | 2 | 2 |
| Primary endpoint: Number of participants affected by dose-limiting toxicities | no commentary found | 0 | 0 |
| Secondary endpoints | discussed | 2 | 2 |
| Population and setting | discussed | 3 | 2 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 4 | 3 |
| Safety and tolerability | discussed | 2 | 2 |
| Design and conduct | discussed | 2 | 2 |
| Access-dependent regimen use | discussed | 6 | 3 |
| DREAMM-7 as an alternative-treatment discussion involving D-Vd | discussed | 7 | 1 |
| Maintenance component selection after contemporary frontline therapy | discussed | 8 | 3 |
| PERSEUS and AURIGA maintenance interpretation and prior CD38 exposure | discussed | 17 | 2 |
| MRD-informed decisions, treatment duration and treatment-free intervals | discussed | 26 | 4 |
| Transplantation after quadruplet induction and selective deferral | discussed | 13 | 2 |
| Contemporary frontline quadruplet rationale and implementation | discussed | 24 | 4 |
| Fitness, cytogenetic work-up and attenuated treatment in older patients | discussed | 22 | 3 |
| French frailty study and dexamethasone minimization | discussed | 9 | 2 |
| Proteasome-inhibitor choice, neuropathy and high-risk treatment intensity | discussed | 18 | 2 |
| Renal impairment and induction sequencing | discussed | 6 | 1 |
| Antibody selection, formulation and patient experience | discussed | 14 | 3 |
| Preparation, preventive care and patient support for combination treatment | discussed | 17 | 2 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 173 statements · 71%** | | | |
| YouTube | 173 | 4 | 6 |
| **Posts · 7 statements · 3%** | | | |
| X threads | 7 | 5 | 28 |
| **Primary sources · 64 statements · 26%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 64 | 6 | not screened |

- Screened window: 2016-05-13 to 2025-08-06
- Cited window: 2017-12-04 to 2025-08-06
- Retrieved: 2026-11-18

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma
- Registry: NCT01998971 (https://clinicaltrials.gov/study/NCT01998971)
- Study IDs: CR103015 · 54767414MMY1001 (Janssen Research & Development, LLC) · 2013-003491-12
- Sponsor: Janssen Research & Development, LLC
- Design: Phase 1 · interventional, non randomized, parallel, phase1
- Status: Completed
- Enrollment: 240 (actual)
- Start: 2014-02-18 (actual)
- Primary completion: 2019-01-31 (actual)
- Primary endpoint: Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT) (Up to 30 days after the last dose of study medication)
- Primary endpoint: Number of participants affected by dose-limiting toxicities (Up to 30 days after the last dose of study medication)
- Intervention: Daratumumab (drug)
- Intervention: Velcade (drug)
- Intervention: Pomalidomide (drug)
- Intervention: Dexamethasone (drug)
- Intervention: Melphalan (drug)
- Intervention: Prednisone (drug)
- Intervention: Thalidomide (drug)
- Intervention: Diphenhydramine (drug)
- Intervention: Acetaminophen (drug)
- Intervention: Carfilzomib (drug)
- Intervention: Lenalidomide (drug)
- Intervention: Montelukast (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on adding daratumumab to pomalidomide and dexamethasone for relapsed or refractory multiple myeloma.
- 4 more clinician views in the sources used in this report are not yet captured as evidence in this edition.
- 98 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 41 sources about other trials or topics are not included.
- The sources reviewed for this edition are not a representative sample of HCP opinion. Organizational shares, patient perspectives, repeated material and unidentified speech cannot be counted as independent clinician agreement.
- Some detailed discussion of MRD-adapted transplantation, ISKIA efficacy and tolerability, preferred MRD thresholds and endpoint recommendations could not be fully assessed, limiting completeness of those sections.
- Full text was unavailable for the initial D-Pd and D-Kd results publications; their available abstracts and later publications provide context but not a complete account of the original reports.
- A separate protocol was not available, and regulatory material was only partially reviewed. Time-specific approval and access statements are reported as expressed, not as current regulatory guidance.
- Many contextual recordings do not name EQUULEUS and concern combinations or treatment phases it did not test. Their relevance to the clinical question does not make them trial results or validate extrapolation to all EQUULEUS cohorts.
- Survey methods, denominators and representativeness were not sufficiently described to convert reported practice variation into prevalence estimates.
- Several numerical descriptions were inconsistent or speculative. They are preserved as attributed interpretations or unresolved wording rather than corrected into clinical facts.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-18 UTC: current edition
  - Routine maintenance: 1 fix (tags):
    - 2026-11-18 UTC: taxonomy mapping corrected

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-18 UTC. No changes.

## Offer

- Size: Standard · 244 verified statements · 93 from 7 confirmed clinicians
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $2,200
- 6 months of updates: $3,100
- 12 months of updates: $4,400
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (7 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/equuleus-nct01998971
- Agents: POST https://www.erudio.com/api/orders with {"report": "equuleus-nct01998971", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=equuleus-nct01998971

## Cite

Erudio Health. EQUULEUS (NCT01998971): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 18, 2026. https://www.erudio.com/reports/equuleus-nct01998971

## Questions

### How much does the EQUULEUS report cost?

One edition costs $1,250 (Standard · 244 verified statements · 93 from 7 confirmed clinicians). With updates: 3 months $2,200, 6 months $3,100, 12 months $4,400. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the EQUULEUS report cover?

244 statements from 15 sources (4 videos, 5 posts, 6 papers), 93 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 18, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the EQUULEUS report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "equuleus-nct01998971" }) previews it and create_order({ "report": "equuleus-nct01998971", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the EQUULEUS report?

Edition 1 (version 1.0.0), accepted Nov 18, 2026 UTC; last checked for new commentary Nov 18, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/equuleus-nct01998971.json
- Markdown: https://www.erudio.com/reports/equuleus-nct01998971.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/equuleus-nct01998971/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "equuleus-nct01998971"}`
